Search

MediciNova Inc

Suletud

SektorTervishoid

1.54 1.32

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.45

Max

1.56

Põhinäitajad

By Trading Economics

Sissetulek

-4.9B

-4.9B

Müük

271K

458K

Aktsiakasum

-0.05

Kasumimarginaal

-1,068,366.946

Töötajad

6

EBITDA

5.1K

-2.5M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+422.88% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

10. nov 2026

Turustatistika

By TradingEconomics

Turukapital

65M

Eelmine avamishind

0.22

Eelmine sulgemishind

1.54

Uudiste sentiment

By Acuity

50%

50%

150 / 340 Pingereas Healthcare

MediciNova Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. aug 2026, 20:02 UTC

MediciNova Inc shares are higher today, continuing a strong upward trend since Friday's close. The stock remains near the upper end of its one-month range.

21. aug 2026, 19:56 UTC

MediciNova Inc's shares are higher today, continuing a positive trend. The stock is trading above its 20-day moving average amid gains in the cryptocurrency sector.

20. aug 2026, 19:16 UTC

MediciNova Inc. shares are lower today, having previously declined significantly before recovering. The price remains above its 20-day moving average.

18. aug 2026, 19:56 UTC

MediciNova Inc shares are higher, reflecting positive market momentum. The stock remains above its 20-day moving average and near the upper end of its one-month range.

17. aug 2026, 19:56 UTC

News

MediciNova shares are higher as the company reported earnings of -$0.05 per share, surpassing estimates and generating $0.46 million in revenue.

13. aug 2026, 19:26 UTC

MediciNova Inc shares are lower amid broader market pressure from rising jobless claims and stabilizing inflation indicators. The stock trades near its one-month range low.

12. aug 2026, 19:56 UTC

MediciNova Inc. shares are trading roughly flat with no specific news identified, remaining near the lower end of their one-month trading range.

11. aug 2026, 20:06 UTC

MediciNova Inc. shares are roughly flat, showing little movement since Monday's close and positioned near the lower end of their one-month trading range.

10. aug 2026, 19:46 UTC

MediciNova Inc shares are lower today, continuing a downward trend since Friday. Broader market sentiment is affected by recent U.S. employment data.

7. aug 2026, 19:46 UTC

MediciNova Inc. shares are higher today, recovering from earlier losses. The stock is trading around the middle of its one-month range.

6. aug 2026, 20:13 UTC

MediciNova Inc shares are higher in after-market trading, reflecting strength since Thursday's close amid rising U.S. Treasury yields and a hawkish Fed outlook.

4. aug 2026, 19:36 UTC

MediciNova Inc. shares are trading roughly flat amid broader market reactions to a decline in U.S. core factory orders and ongoing strength in AI sectors.

3. aug 2026, 20:06 UTC

MediciNova Inc. shares are lower, continuing a decline since Friday's close, despite positive movements in major indices like the S&P 500 and Nasdaq 100.

31. juuli 2026, 19:56 UTC

Shares of MediciNova Inc. are lower during Friday's session, following a routine decline after an early high. The stock is below its 20-day moving average.

30. juuli 2026, 20:51 UTC

MediciNova Inc's shares are lower in after-market hours, reflecting a broader decline in the Biotechnology sub-sector. The asset is near its one-month trading range low.

29. juuli 2026, 20:09 UTC

MediciNova Inc shares are lower today, continuing a decline since Tuesday's close, and remain near their opening low amid broader market trends.

28. juuli 2026, 18:46 UTC

MediciNova Inc. shares are trading higher today, remaining above Monday's close despite settling back from earlier gains during the session.

27. juuli 2026, 19:06 UTC

MediciNova Inc. shares are lower today, reflecting broader market trends amid a significant decline in crude oil prices following eased geopolitical tensions.

24. juuli 2026, 23:02 UTC

MediciNova Inc shares increased in after-hours trading, reflecting strong performance since Friday's close, despite mixed market sentiment and no specific company news.

23. juuli 2026, 20:06 UTC

MediciNova Inc. shares are lower today, continuing a six-session decline amid routine volatility and remaining significantly below the 20-day moving average.

21. juuli 2026, 19:21 UTC

MediciNova Inc. shares are lower amid no specific news, continuing a trend below the 20-day moving average over the past three sessions.

Võrdlus sarnastega

Hinnamuutus

MediciNova Inc Prognoos

Hinnasiht

By TipRanks

422.88% tõus

12 kuu keskmine prognoos

Keskmine 8 USD  422.88%

Kõrge 10 USD

Madal 6 USD

Põhineb 2 Wall Streeti analüütiku instrumendi MediciNova Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

150 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
help-icon Live chat